What patients take without telling you: holistic approach for BPH

被引:6
作者
Capodice, Jillian L. [1 ]
Katz, Aaron E. [1 ]
机构
[1] Columbia Presbyterian Med Ctr, Ctr Holist Urol, Dept Urol, New York, NY 10032 USA
关键词
benign prostatic hyperplasia (BPH); herbs;
D O I
10.1007/s00345-006-0093-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The use of botanicals and supplements have markedly increased in men that are seeking increased protection against the potential onset and symptomatic relief of lower urinary tract symptoms that are commonly experienced with benign prostatic hyperplasia (BPH). While this implies a positive trend and considers that men are taking a more active role in health and prevention, dialog between the patient and the clinician is often deficient. This may be due to a number of factors including both the patients' inability to report about the use of certain agents and the clinicians' inability to ask. Moreover, the sense that natural agents may lack side effects coupled with ineffective communication between the doctor and patient could result in potential adverse interactions. We have performed a comprehensive search of articles published from 1990 to 2005 using the Medline databases in order examine clinical data on the most commonly researched herbs for BPH. We provide a brief update on the state of the research.
引用
收藏
页码:378 / 382
页数:5
相关论文
共 43 条
[1]
Anderson Mark L., 2005, Journal of Herbal Pharmacotherapy, V5, P17, DOI 10.1080/J157v05n01_03
[2]
[Anonymous], 2002, COCHRANE DB SYST REV
[3]
In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells [J].
Awad, AB ;
Fink, CS ;
Williams, H ;
Kim, U .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2001, 10 (06) :507-513
[4]
Effect of β-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells [J].
Awad, AB ;
Gan, YM ;
Fink, CS .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2000, 36 (01) :74-78
[5]
Evaluation and medical management of benign prostatic hyperplasia [J].
Beckman, TJ ;
Mynderse, LA .
MAYO CLINIC PROCEEDINGS, 2005, 80 (10) :1356-1362
[6]
RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL-TRIAL OF BETA-SITOSTEROL IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA [J].
BERGES, RR ;
WINDELER, J ;
TRAMPISCH, HJ ;
SENGE, T ;
AEIKENS, B ;
ALBRECHT, J ;
BECKER, C ;
BRUNDIG, P ;
DREYER, D ;
KALDEWEY, W ;
LATKA, H ;
REEK, A ;
SCHNEIDER, HJ ;
SCHOTER, P ;
SCHUMACHER, C .
LANCET, 1995, 345 (8964) :1529-1532
[7]
Treatment of symptomatic benign prostatic hyperplasia with β-sitosterol:: an 18-month follow-up [J].
Berges, RR ;
Kassen, A ;
Senge, T .
BJU INTERNATIONAL, 2000, 85 (07) :842-846
[8]
Bressler R, 2005, GERIATRICS, V60, P32
[9]
Efficacy and acceptability of Tadenan® (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH):: A multicentre trial in central Europe [J].
Breza, J ;
Dzurny, O ;
Borowka, A ;
Hanus, T ;
Petrik, R ;
Blane, G ;
Chadha-Boreham, H .
CURRENT MEDICAL RESEARCH AND OPINION, 1998, 14 (03) :127-139
[10]
Brown Gordon A, 2004, J Am Osteopath Assoc, V104, pS11